Verona Pharma Plc Stock Performance
| VRNA Stock | USD 38.81 0.95 2.51% |
On a scale of 0 to 100, Verona Pharma holds a performance score of 16. The entity has a beta of 0.29, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Verona Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Verona Pharma is expected to be smaller as well. Please check Verona Pharma's skewness, and the relationship between the potential upside and rate of daily change , to make a quick decision on whether Verona Pharma's existing price patterns will revert.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Verona Pharma PLC are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Verona Pharma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.04 | Five Day Return 10.34 | Year To Date Return 105.37 | Ten Year Return 186.15 | All Time Return 186.15 |
1 | Chronic Obstructive Pulmonary Disease Market Forecast Report and Company Analysis 2024-2032 Featuring AstraZeneca, Pfizer, GSK, Novartis, Astellas, Abbott, Boeh... | 09/10/2024 |
2 | Disposition of 249728 shares by Mark Hahn of Verona Pharma at 4.3807 subject to Rule 16b-3 | 10/18/2024 |
3 | Disposition of 159344 shares by Mark Hahn of Verona Pharma at 4.3849 subject to Rule 16b-3 | 10/22/2024 |
4 | Disposition of 140000 shares by David Zaccardelli of Verona Pharma at 4.3773 subject to Rule 16b-3 | 10/24/2024 |
5 | Acquisition by Andrew Fisher of 300000 shares of Verona Pharma subject to Rule 16b-3 | 10/30/2024 |
6 | Disposition of 245952 shares by Mark Hahn of Verona Pharma at 4.2412 subject to Rule 16b-3 | 11/01/2024 |
7 | Verona Pharma PLC Q3 2024 Earnings Call Highlights Strong Ohtuvayre Launch Amid Rising Costs | 11/05/2024 |
8 | Verona Pharma PLC CFO Mark Hahn Sells 129,672 Shares | 11/06/2024 |
9 | Verona Pharma director Christina Ackermann acquires 198,385 in shares | 11/07/2024 |
10 | Verona Pharma plc CEO Sells 413,292.16 in Stock | 11/08/2024 |
11 | Disposition of 2400 shares by Mark Hahn of Verona Pharma at 5.0 subject to Rule 16b-3 | 11/11/2024 |
12 | FMR LLC Acquires Significant Stake in Verona Pharma PLC | 11/13/2024 |
13 | RA Capital Management, L.P. Expands Stake in Verona Pharma PLC | 11/15/2024 |
14 | Verona Pharma director David Ebsworth buys 88,800 in shares | 11/18/2024 |
15 | While shareholders of Verona Pharma are in the black over 5 years, those who bought a week ago arent so fortunate | 11/19/2024 |
| Begin Period Cash Flow | 227.8 M | |
| Free Cash Flow | -50.2 M |
Verona |
Verona Pharma Relative Risk vs. Return Landscape
If you would invest 2,669 in Verona Pharma PLC on August 24, 2024 and sell it today you would earn a total of 1,212 from holding Verona Pharma PLC or generate 45.41% return on investment over 90 days. Verona Pharma PLC is currently generating 0.6304% in daily expected returns and assumes 3.0122% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Verona, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Verona Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Verona Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Verona Pharma PLC, and traders can use it to determine the average amount a Verona Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2093
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VRNA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.01 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.63 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Verona Pharma is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Verona Pharma by adding it to a well-diversified portfolio.
Verona Pharma Fundamentals Growth
Verona Stock prices reflect investors' perceptions of the future prospects and financial health of Verona Pharma, and Verona Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Verona Stock performance.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.94) % | ||||
| Current Valuation | 2.88 B | ||||
| Shares Outstanding | 81.83 M | ||||
| Price To Earning | (9.15) X | ||||
| Price To Book | 23.74 X | ||||
| Price To Sales | 550.88 X | ||||
| Revenue | 458 K | ||||
| Gross Profit | 112 K | ||||
| EBITDA | (52.47 M) | ||||
| Net Income | (54.58 M) | ||||
| Cash And Equivalents | 111.51 M | ||||
| Cash Per Share | 1.83 X | ||||
| Total Debt | 51.33 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.57 X | ||||
| Book Value Per Share | 1.59 X | ||||
| Cash Flow From Operations | (50.22 M) | ||||
| Earnings Per Share | (2.00) X | ||||
| Market Capitalization | 3.1 B | ||||
| Total Asset | 308.12 M | ||||
| Retained Earnings | (388.43 M) | ||||
| Working Capital | 281.02 M | ||||
About Verona Pharma Performance
By analyzing Verona Pharma's fundamental ratios, stakeholders can gain valuable insights into Verona Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Verona Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Verona Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Verona Pharma PLC performance evaluation
Checking the ongoing alerts about Verona Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Verona Pharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Verona Pharma PLC appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 458 K. Net Loss for the year was (54.58 M) with profit before overhead, payroll, taxes, and interest of 112 K. | |
| Verona Pharma PLC currently holds about 111.51 M in cash with (50.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83. | |
| Verona Pharma PLC has a frail financial position based on the latest SEC disclosures | |
| Over 89.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from simplywall.st: While shareholders of Verona Pharma are in the black over 5 years, those who bought a week ago arent so fortunate |
- Analyzing Verona Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Verona Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Verona Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Verona Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Verona Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Verona Pharma's stock. These opinions can provide insight into Verona Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Verona Stock analysis
When running Verona Pharma's price analysis, check to measure Verona Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verona Pharma is operating at the current time. Most of Verona Pharma's value examination focuses on studying past and present price action to predict the probability of Verona Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verona Pharma's price. Additionally, you may evaluate how the addition of Verona Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |